html On June 30, the 2022 China (Zhejiang) Pilot Free Trade Zone Life and Health Industry Promotion Conference and the 6th International Biomedicine (Hangzhou) Innovation Summit opened in Qiantang District.
Under centralized procurement, is the pharmaceutical industry facing challenges or new opportunities? What are the prospects and future development trends of the cell and gene therapy industry? How will the investment and financing hot spots and trends in the pharmaceutical industry fluctuate? At the
conference, experts from well-known pharmaceutical companies and investment and financing industries at home and abroad gathered together to focus on the institutional dividends and policy integration advantages of the Zhejiang Pilot Free Trade Zone, and how to promote the high-quality development of the entire biomedicine entire industrial chain . Provide advice and suggestions for the development of biomedical industry.
Zhejiang Pilot Free Trade Zone
Zhejiang Pilot Free Trade Zone was officially established on April 1, 2017, and achieved “area expansion and upgrade” on August 30, 2020, forming a development pattern of “one zone and four areas”. So far, it has accumulated 335 institutional innovation achievements were formed, of which 113 were the first in the country and 31 were replicated and promoted nationwide.
html Over the past 2005 years, the Zhejiang Pilot Free Trade Zone has continued to deepen institutional innovation, reform integration, and project implementation, and has become a pioneer demonstration zone that serves major national strategies and promotes high-quality economic development.
This summit interpreted the "Action Plan to Promote the High-Quality Development of the Biomedical Industry (2022-2024)" and released the "Hangzhou Medical Port Biomedical Industry Innovation Development Plan" on-site.
As Zhejiang Province’s new industrial platform of “10,000 acres and 100 billion”, Hangzhou Medical Port is becoming the core area for the development of the province’s biopharmaceutical industry. Data is the best evidence. In 2021, Hangzhou Medical Port biopharmaceutical companies achieved revenue of 45 billion yuan, a year-on-year increase of 12%, and completed 35 signed projects of more than 100 million yuan, 11 projects of more than 1 billion yuan, and a total investment of 23.26 billion. Yuan.
Currently, Hangzhou Medical Port has gathered more than 1,500 biopharmaceutical companies. Merck, Abbott, Johnson & Johnson, and other 7 of the world's top 10 pharmaceutical companies have settled here. It has also attracted 29 institutions such as the Institute of Basic Medicine and Oncology of the Chinese Academy of Sciences. Public service platforms have been established one after another. The achievements of
are inseparable from the integrated development of Hangzhou Medical Port through the "six chains" of industrial chain, innovation chain, ecological chain, talent chain, financial chain and service chain. For example, in terms of the policy chain, Class I innovative drugs are provided with 40% investment in R&D, with a maximum financial support of 48 million yuan.
At the summit, projects in the biomedical field such as the Sri Lankan Microbiology Project, the Wenda Pharmaceutical Project, the Hangzhou Municipal Health Commission Transformation Center Project, and the Zhejiang University Institute of Biological Sciences Project were signed and settled in Qiantang, injecting fresh blood into the biomedical industry in Qiantang District.
The opening ceremony also held a signing ceremony for strategic cooperation between the Biomedical Industry Fund and Heda Biomedical Industrial Park infrastructure investment business. At the same time, the "Provincial Innovation and Entrepreneurship Base for Overseas Chinese" in Hangzhou Dachuang Town was officially awarded, the Zhejiang Provincial Biomedical Industry Research Alliance was established, and the "Yangtze River Delta Biomedical Industry White Paper" was released.
In addition, the Hangzhou area of the Zhejiang Pilot Free Trade Zone has officially launched a pilot project for the joint safety supervision mechanism for entry of special items, aiming to further optimize the entry management procedures for special items and effectively solve the deep-seated problems in enterprise development. Aibo Biotechnology and Qihan Biotechnology have become the first batch Whitelist companies. (Reporters: Hao Shuang, Zhu Sheng)
